Investor Expectations for the Life Sciences Sector
A panel of healthcare and finance experts will discuss the results from FTI Consulting's Fourth Annual Life Sciences Survey and explore the market dynamics currently driving investment decisions and transactions in the industry.
Date Presented
March 13, 2014
Length
60 minutes
View Replay
Panel
Judy BrownExecutive Vice President and Chief Financial Officer, Perrigo CompanyJudy Brown is an executive vice president and chief financial officer at Perrigo Company, a leading global manufacturer and distributor of over-the-counter (OTC) pharmaceuticals. At Perrigo, she has overseen the acquisition of Dublin-based biotechnology company, Elan. She currently is on the board of directors at Belden Corporation (NYSE: BDC), a connectivity and networking products manufacturer.
Learn About
Investors’ outlook for healthcare and life sciences stock performance
Key drivers of investment decisions, and valuations for public and private companies
Expectations for industry IPOs and M&A activity in 2014
Regulations impacting the sector and transaction environment
Key trends in shareholder engagement and communication strategies for enhancing enterprise value
Alan HartmanPartner, Centerview PartnersAlan Hartman is a partner at New York-based investment-banking and private-equity firm, Centerview Partners. With more than 20 years of experience in mergers and acquisitions, he has established himself as a leading expert in healthcare-industry transactions -- having recently advised Pfizer in its $68 billion acquisition of Wyeth, and $12 billion sale of its nutrition business to Nestle; and Onyx in its $10.4 billion sale to Amgen.
Who Should Watch This Webinar
Buy-Side Investors
Business Development Professionals
Chief Communications Officers (CCOs)
C-Suite Executives
Investment Bankers
Investor Relations Officers (IROs)
Lawyers
Sell-Side Analysts
Venture Capitalists
Healthcare & Life Sciences
About the Research
FTI Consulting’s Fourth Annual Life Sciences Investor Survey assesses European and U.S. investors’ insights and expectations around a number of key industry-related topics. The study’s findings underscore investors’ overall optimism toward the outlook for healthcare stock performance and the anticipated continued strength of the transaction environment in the sector. The research also reveals a number of key trends in shareholder engagement for healthcare and life sciences companies to consider.
Tom CrawfordSenior Managing Director, Government Affairs, FTI Consulting Tom Crawford is a senior managing director in the Strategic Communications segment at FTI Consulting and serves as head of its Government Affairs specialty practice (formerly C2 Group) in the Americas. He has worked on every budget reconciliation and tax-measure package considered by the U.S. Congress in the past two decades, and has represented some the largest and most eminent financial-services and life-insurance companies.
Barbara RyanManaging Director, Financial Communications, FTI Consulting Barbara Ryan is a managing director in the Strategic Communications segment at FTI Consulting, and is based in New York. Ms. Ryan has more than 30 years of Wall Street experience as a sell-side analyst and is an expert on the biopharmaceutical and healthcare industry. She has been widely published as an authority on the trends and outlook for the global pharmaceutical industry; and is a regular, guest contributor to CNBC. Prior to FTI Consulting, Ms. Ryan was a managing director at Deutsche Bank, and head of its pharmaceutical-research teams.